The expression and prognostic value of miR-146a and miR-155 in Turkish patients with multiple sclerosis

Significant cognitive impairment has been found in 20—30% of patients with clinically isolated syndromes suggestive of multiple sclerosis. In this study we aimed to assess the prognostic value of the presence of cognitive impairment for the conversion to multiple sclerosis in patients with clinically isolated syndromes. All patients with clinically isolated syndromes consecutively referred to our centre since 2002 and who had been followed-up for at least one year underwent cognitive assessment through the Rao’s Battery and the Stroop test. Possible predictors of conversion to clinically definite multiple sclerosis were evaluated through the Kaplan Meier curves and Cox regression analysis. A total of 56 patients (41 women; age 33.2 ± 8.5 years; expanded disability scale score 1.2 ± 0.7) were recruited. At baseline, 32 patients (57%) fulfilled McDonald’s criteria for dissemination in space. During the follow-up (3.5 ± 2.3 years), 26 patients (46%) converted to a diagnosis of multiple sclerosis. In particular, 64% of patients failing ≥ 2 tests and 88% of patients failing ≥ 3 tests converted to multiple sclerosis. In the Cox regression model, the failure of at least three tests (HR 3.3; 95% CI 1.4—8.1; p = 0.003) and the presence of McDonald’s dissemination in space at baseline (HR 3.8; 95% CI 1.5—9.7; p = 0.005), were found to be predictors for conversion to multiple sclerosis. We conclude that cognitive impairment is detectable in a sizable proportion of patients with clinically isolated syndromes. In these subjects cognitive impairment has a prognostic value in predicting conversion to multiple sclerosis and may therefore play a role in therapeutic decision making.

Download Full-text

A prognostic value of the study of the exposure of glycosyl determinants to IgG molecules in the blood serum of patients with multiple sclerosis depending on the performed drug therapy

INTERNATIONAL NEUROLOGICAL JOURNAL ◽

10.22141/2224-0713.16.5.2020.209246 ◽

2020 ◽

Vol 16 (5) ◽

pp. 11-17

Author(s):

M.O. Boichuk ◽

T.I. Nehrych ◽

R.O. Bilyy

Keyword(s):

Multiple Sclerosis ◽

Drug Therapy ◽

Blood Serum ◽

Prognostic Value

Download Full-text

Prognostic value of cerebrospinal fluid IgA and IgG in multiple sclerosis

Multiple Sclerosis Journal ◽

10.1191/1352458504ms1052sr ◽

2004 ◽

Vol 10 (4) ◽

pp. 469-471 ◽

Cited By ~ 6

Author(s):

Magnus Vrethem ◽

Ingrid Fernlund ◽

Jan Ernerudh ◽

Sten Öhman

Keyword(s):

Multiple Sclerosis ◽

Cerebrospinal Fluid ◽

Experimental Design ◽

Prognostic Value ◽

Walking Distance ◽

Iga Antibodies ◽

A Prospective Study ◽

Myelin Degradation ◽

Walking Aid

IgA antibodies do not activate complement and may compete with and protect against myelin degradation caused by IgM and IgG in multiple sclerosis (MS). We retrospectively evaluated cerebrospinal fluid (CSF) IgA and IgG (as indices and extended indices) from 1980 to 1988 in 68 patients with definitive MS. Sixty-one of them had survived since the time of sampling (11- 19 years). IgA Extended Index was significantly higher for surviving patients (median 0.65) than for the dead patients (median 0.33). CSF IgA or IgG indices did not correlate with disability, walking distance, or time from onset of symptoms to the need of walking aid. The retrospective experimental design allowed an unusually long follow-up time, but it also had the disadvantages of such a study. Thus the results warrant a prospective study to verify the prognostic vale of CSF IgA in MS.

Download Full-text

Long-term prognostic value of longitudinal measurements of blood neurofilament levels

Neurology Neuroimmunology & Neuroinflammation ◽

10.1212/nxi.0000000000000856 ◽

2020 ◽

Vol 7 (5) ◽

pp. e856 ◽

Cited By ~ 2

Author(s):

Dieter A. Häring ◽

Harald Kropshofer ◽

Ludwig Kappos ◽

Jeffrey A. Cohen ◽

Anuja Shah ◽

...

Keyword(s):

Multiple Sclerosis ◽

Light Chain ◽

Prognostic Value ◽

Long Term Outcomes ◽

Neurofilament Light Chain ◽

Neurofilament Light ◽

Longitudinal Measurements ◽

Relapsing Remitting ◽

Edss Score

ObjectiveTo assess the long-term prognostic value of an integral of longitudinal measurements of plasma neurofilament light chain levels (NfLlong) over 12 and 24 months vs single neurofilament light chain (NfL) measurements in patients with relapsing-remitting MS (RRMS) and its additional value when combined with clinical and MRI measures.MethodsThis analysis included continuously fingolimod-treated patients with RRMS from the 24-month FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis (FREEDOMS)/12-month Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS) phase 3 trials and their long-term extension, LONGTERMS. Patients were classified into high (≥30 pg/mL, n = 110) and low (<30 pg/mL, n = 164) NfL categories based on the baseline (BL) NfL value or the geometric mean NfLlong calculated over 12 and 24 months to predict disability-related outcomes and brain volume loss (BVL). The additional prognostic value of NfL was quantified using the area under the receiver operating characteristic (ROC) curve.ResultsA single high (vs low) NfL measure at BL was prognostic of a higher risk of reaching Expanded Disability Status Scale (EDSS) score ≥4 earlier (hazard ratio [HR] = 2.19; 95% CI = 1.21–3.97) and higher BVL over 120 months (difference: −1.12%; 95% CI = −2.07 to −0.17). When NfLlong was measured over 24 months, high NfL was associated with a higher risk of reaching EDSS score ≥4 (HR = 7.91; 95% CI = 2.99–20.92), accelerated 6-month confirmed disability worsening (HR = 3.14; 95% CI = 1.38–7.11), and 20% worsening in the Timed 25-Foot Walk Test (HR = 3.05; 95% CI = 1.38–6.70). Area under the ROC curve was consistently highest in models combining NfL with clinical and MRI measures.ConclusionsNfLlong had a higher prognostic value than single NfL assessments on long-term outcomes in RRMS. Combining it with clinical and MRI measures increased sensitivity and specificity to predict long-term disease outcomes.Classification of evidenceThis study provides Class I evidence that NfLlong was more strongly associated with long-term outcomes than single NfL assessments in patients with RRMS.

Download Full-text

Potential prognostic value of circulating inflamma-miR-146a-5p and -125a-5p in relapsing-remitting multiple sclerosis

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2021.103126 ◽

2021 ◽

pp. 103126

Author(s):

Angelica Giuliani ◽

Simona Lattanzi ◽

Deborah Ramini ◽

Laura Graciotti ◽

Maura Chiara Danni ◽

...

Keyword(s):

Multiple Sclerosis ◽

Prognostic Value ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

HLA genotypes in turkish patients with myasthenia gravis: Comparison with multiple sclerosis patients on the basis of clinical subtypes and demographic features

Human Immunology ◽

10.1016/j.humimm.2004.05.004 ◽

2004 ◽

Vol 65 (7) ◽

pp. 752-757 ◽

Cited By ~ 15

Author(s):

Berril Dönmez ◽

Serkan Özakbas ◽

Mehmet Ali Öktem ◽

Muhtesem Gedizlioglu ◽

Isil Coker ◽

...

Keyword(s):

Multiple Sclerosis ◽

Myasthenia Gravis ◽

Hla Genotypes ◽

Multiple Sclerosis Patients ◽

Turkish Patients ◽

Demographic Features

Download Full-text

The Importance and Utility of Cerebrospinal Fluid Evaluation in the Diagnosis of Central Demyelinating Diseases

10.1093/med/9780199341016.003.0008 ◽

2016 ◽

Cited By ~ 1

Author(s):

Mark S. Freedman ◽

Mohammad Abdoli

Keyword(s):

Multiple Sclerosis ◽

Cerebrospinal Fluid ◽

Prognostic Value ◽

Clinically Isolated Syndrome ◽

Demyelinating Diseases ◽

Response To Treatment ◽

Disease Subtype ◽

Csf Analysis ◽

Diagnostic And Prognostic Value ◽

Csf Findings

This chapter aims to highlight the diagnostic and prognostic value of cerebrospinal fluid (CSF) findings in multiple sclerosis with a special consideration of distinguishing it from neuromyelitis optica (NMO) and NMO spectrum disorder. Interpretation of CSF findings in daily clinical practice in patients with MS is thoroughly explained. New advances in CSF analysis and recently identified biomarkers may be helpful for diagnosis, help elucidate disease subtype and activity, or aid in prognosis and monitoring of the response to treatment. Characteristics of CSF changes in different subtypes of multiple sclerosis, clinically isolated syndrome (CIS), and radiologically isolated syndrome (RIS) are discussed. CSF findings in NMO spectrum disease as a diagnostic and differentiating marker are explained separately.

Download Full-text